Hemab Therapeutics Holdings, Inc. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Hemab Therapeutics Holdings, Inc. (COAG) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $0 as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-08-11
- 2026-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $0.00.
- 2026-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $0.00.
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $500.00K.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-11 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-21 |
| 2025-12-31 | $500.00K 10-Q · filed 2026-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |